Clinical Effect of Guanxin Shutong Capsules in Treating Coronary Heart Failure with Heart Blood Stasis

WANG Yaqin; ZHANG Yan; ZHANG Wei

doi:10.13422/j.cnki.syfjx.20231494

您当前的位置：

首页 >

文章列表页 >

Clinical Effect of Guanxin Shutong Capsules in Treating Coronary Heart Failure with Heart Blood Stasis

更新时间：2023-05-17

- Clinical Effect of Guanxin Shutong Capsules in Treating Coronary Heart Failure with Heart Blood Stasis
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 29, Issue 7, Pages: 153-159(2023)
- 作者机构：
  
  1.辽宁中医药大学，沈阳 110085
  2.辽宁中医药大学附属医院，沈阳 110085
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20231494
  CLC： R242;R2-031;R287;R541.6;R256.2
- Published：05 April 2023，
  
  Published Online：31 January 2023，
  
  Received：06 October 2022，
- 稿件说明：
扫描看全文
王雅琴,张艳,张伟.冠心舒通胶囊治疗心血瘀阻型冠心病心力衰竭的临床疗效[J].中国实验方剂学杂志,2023,29(07):153-159.

WANG Yaqin,ZHANG Yan,ZHANG Wei.Clinical Effect of Guanxin Shutong Capsules in Treating Coronary Heart Failure with Heart Blood Stasis[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(07):153-159.
王雅琴,张艳,张伟.冠心舒通胶囊治疗心血瘀阻型冠心病心力衰竭的临床疗效[J].中国实验方剂学杂志,2023,29(07):153-159. DOI： 10.13422/j.cnki.syfjx.20231494.

WANG Yaqin,ZHANG Yan,ZHANG Wei.Clinical Effect of Guanxin Shutong Capsules in Treating Coronary Heart Failure with Heart Blood Stasis[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(07):153-159. DOI： 10.13422/j.cnki.syfjx.20231494.

摘要

目的

探讨冠心舒通胶囊用于冠心病心力衰竭心血瘀阻证患者的临床疗效。

方法

研究选取2020年6月至2022年8月就诊于辽宁中医药大学附属医院专家门诊并被诊断为冠心病心力衰竭心血瘀阻证的患者98例。将98例患者采用随机表法分为对照组、观察组各49例，两组患者均根据指南采用冠心病心力衰竭规范化治疗，观察组在此基础上加用中成药冠心舒通胶囊，对比两组治疗前后心脏结构功能指标、症状疗效总有效率、运动耐力、心率变异性、生活质量、炎症因子水平。

结果

治疗前，两组患者在超敏C反应蛋白（hs-CRP）、6 min步行试验（6MWT）、明尼苏达心力衰竭生活质量量表（MLHFQ）、左室射血分数（LVEF）、肿瘤坏死因子-

（TNF-

）、左室舒张末内径（LVEDD）、N-末端B型脑钠肽前体（NT-proBNP）、心率变异性（HRV）方面对比差异无统计学意义，资料具有可比性。治疗后，与对照组比较，观察组患者中医证候有效率（

=-2.362，

0.05）及美国纽约心脏病协会（NYHA）心功能分级有效率（

=-2.175，

0.05）均优于对照组，差异具有统计学意义。与本组治疗前比较，两组患者治疗后MLHFQ、LVEDD、TNF-

、NT-proBNP、hs-CRP水平均明显降低（

0.05，

0.01）；与对照组治疗后比较，观察组患者改善更明显（

0.05，

0.01）。与本组治疗前比较，两组患者治疗后6MWT、LVEF、HRV均显著升高（

0.01）；与对照组治疗后比较，观察组患者改善更显著（

0.01）。

结论

冠心舒通胶囊联合规范化治疗能够改善慢性心力衰竭心血瘀阻证患者的躯体症状，提高患者的运动耐量及生活质量，减轻炎症反应，提高心率变异性，改善心脏结构和功能。

Abstract

Objective

To investigate the clinical effect of Guanxin Shutong capsules （GXSTC） on coronary heart failure with heart blood stasis.

Method

A total of 98 coronary heart failure patients with heart blood stasis who visited the expert clinics of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine from June 2020 to August 2022 were selected. They were randomized into a control group and an observation group， with 49 in each group. The two groups were given standardized treatment according to the guidelines for coronary heart failure. On this basis， the observation group was treated with Chinese patent medicine GXSTC. The cardiac structural and functional indicators， total effective rate of symptoms， exercise tolerance， heart rate variability （HRV）， quality of life and inflammatory factor levels of the two groups before and after treatment were compared.

Result

Before treatment， there was no notable difference in high-sensitivity C-reactive protein （hs-CRP）， six minute walk test （6MWT）， minnesota living with heart failure questionnaire （MLHFQ） score， left ventricular ejection fraction （LVEF）， tumor necrosis factor-

（TNF-

）， left ventricular end-diastolic diameter （LVEDD）， N-terminal pro-brain natriuretic peptide （NT-proBNP） and HRV between the two groups， and thus the data were comparable. After treatment， the observation group had higher effective rates of traditional Chinese medicine （TCM） symptoms （

=-2.362，

0.05） and New York heart association class （NYHA） functional classes （

=-2.175，

0.05） than the control group. The two groups presented decreased LVEDD， TNF-

， NT-proBNP and hs-CRP （

0.05，

0.01） while increased MLHFQ， 6MWT and HRV（

0.05，

0.01） after treatment as compared with those before treatment， and the observation group had more decrease or increase than the control group （

0.05，

0.01）.

Conclusion

GXSTC combined with standardized treatment relieves the physical symptoms of coronary heart failure patients with heart blood stasis， improves exercise tolerance and quality of life， reduces inflammatory reaction， increases HRV， and improves cardiac structure and function.

关键词

冠心病心力衰竭冠心舒通胶囊心率变异性炎症因子水平

Keywords

coronary heart failureGuanxin Shutong capsulesheart rate variabilityinflammatory factor level

references

BEGGS S A S，MCDONAGH T A，GARDNER R S.Chronic heart failure：Epidemiology，investigation and management［J］.Medicine，2018，doi：10.1016/j.mpmed.2018.07.006http://dx.doi.org/10.1016/j.mpmed.2018.07.006.

SANTULLI G，WANG X，MONE P.Updated ACC/AHA/HFSA 2022 guidelines on heart failure：What is new？ From epidemiology to clinical management［J］.Eur Heart J Cardiovasc Pharmacother，2022，8（5）：e23-e24.

ZHANG M，CHUA H Z，ZHANG J，et al.Developing a core outcome set on traditional Chinese medicine （COS-TCM） for chronic heart failure （CHF）：A study protocol［J］.BMJ Open，2021，11（7）：e047148.

崔鑫，韩晟，李军，等.冠心舒通胶囊治疗冠心病心绞痛心血瘀阻证的临床综合评价［J］.中国中药杂志，2022，47（6）：1469-1475.

胡文文.冠心舒通胶囊结合蒙药八味沉香散治疗冠心病的临床效果［J］.中国民族医药杂志，2021，27（3）：9-11.

邓霞，刘江红，刘鸿涛.冠心舒通胶囊联合西医治疗急性冠脉综合征经皮冠状动脉介入术后心绞痛临床研究［J］.中国药业，2020，29（24）：70-73.

张艳，王懿，礼海，等.冠心舒通胶囊对心衰大鼠ATP代谢影响的实验研究［J］.世界中西医结合杂志，2016，11（11）：1523-1525，1531.

张艳，廖佳丹，王辰，等.冠心舒通胶囊对慢性心力衰竭大鼠心肌组织MMP-9的影响［J］.上海中医药大学学报，2012，26（6）：83-85.

张艳，刘秀娜，王懿，等.冠心舒通胶囊对慢性心力衰竭大鼠心肌能量代谢的影响［J］.中医杂志，2015，56（23）：2054-2057.

张艳，王辰，宫丽鸿，等.冠心舒通胶囊对慢性心衰模型大鼠AT1、ERK2的影响［J］.国际中医中药杂志，2013，35（1）：37-39.

中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014［J］.中华心血管病杂志，2014，42（2）：98-122.

中华医学会心血管病学分会介入心脏病学组，中华医学会心血管病学分会动脉粥样硬化与冠心病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，等.稳定性冠心病诊断与治疗指南［J］.中华心血管病杂志，2018，46（9）：680-694.

郑筱萸.中药新药临床研究指导原则［M］.北京：中国医药科技出版社，2002：68-73.

中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018［J］.中华心血管病杂志，2018，46（10）：760-789.

HEIDENREICH P A，FONAROW G C，BREATHETT K，et al.2020 ACC/AHA Clinical performance and quality measures for adults with heart failure：A report of the American College of Cardiology/American Heart Association task force on performance measures［J］.Circ Cardiovasc Qual Outcomes，2020，13（11）：e000099.

MANITO N.New 2021 ESC/HFA heart failure guidelines.A practical comprehensive approach.［J］.Rev Esp Cardiol （Engl Ed），2022，75（7）：548-551.

CHEN X，XIN Y，HU W，et al.Quality of life and outcomes in heart failure patients with ejection fractions in different ranges［J］.PLoS One，2019，14（6）：e0218983.

CHEN S，ZHOU Y，WU X，et al.The value of echocardiography combined with NT-pro BNP level in assessment and prognosis of diastolic heart failure［J］.Comput Math Methods Med，2022，2022：2102496.

HENDRICKS S，DYKUN I，BALCER B，et al.Higher BNP/NT-pro BNP levels stratify prognosis equally well in patients with and without heart failure：A Meta-analysis［J］.ESC Heart Fail，2022，9（5）：3198-3209.

LIU Z，XV Y，LIU X，et al.Associations of systemic inflammatory markers with the risks of chronic heart failure：A case-control study［J］.Clinics （Sao Paulo），2022，77：100056.

LATEEF A S，JUMAA S，MUTAR A A R.Evaluation of some biochemical markers in patients serum of myocardial infarction and heart failure［J］.Indian J Public Health，2019，10（4）：369-373.

ELAHI M，ASOPA S，MATATA B.NO-cGMP and TNF-alpha counter regulatory system in blood：Understanding the mechanisms leading to myocardial dysfunction and failure［J］.Biochim Biophys Acta，2007，1772（1）：5-14.

NAPOLEÃO P，SANTOS M C，SELAS M，et al.Variations in inflammatory markers in acute myocardial infarction：a longitudinal study［J］.Rev Port Cardiol，2007，26（12）：1357-1363.

刘姝.冠心舒通胶囊对冠心病患者炎症因子水平和血流动力的影响［J］.辽宁中医杂志，2021，48（10）：92-95.

徐季轩，马晓静，陈泓颖，等.我国主要少数民族医药防治缺血性心脏病研究概述［J］.中国实验方剂学杂志，2022，28（17）：235-247.

陈志洁，汪春庆，康小琴，等.HRV参数与AMI患者梗死部位、病变血管支数及预后的关系［J］.影像科学与光化学，2022，40（4）：804-809.

ACHARYA U R，FUJITA H，SUDARSHAN V K，et al.Application of empirical mode decomposition （EMD） for automated identification of congestive heart failure using heart rate signals［J］.Neural Comput Appl，2017，doi：10.1007/s00521-016-2612-1http://dx.doi.org/10.1007/s00521-016-2612-1.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Effect of Tiaomai Mixture on Premature Ventricular Contraction in Coronary Heart Disease Due to Qi-Yin Deficiency and Stagnated Heat in Blood Vessel

Clinical Efficacy and Mechanism of Xiao Qinglongtang in Treating Chronic Heart Failure with Cold Phlegm in Lung

Protective Effects of Guanxin Shutong Capsules and its Single Herbs against Injury for Myocardial Cells and Aortal Smooth Muscle Cells

Effect of Wenyang Huoxue Jiedu Decoction on Testosterone and Heart Rate Variability in Male Patients with Chronic Heart Failure

Effect of Taohong Siwutang on Heart Rate Variability, Blood Lipids and CRP of Patients of Phlegm and Blood Stasis Type Diabetes Mellitus with Atherosclerosis

Related Author

Zhi-zhen WEI

Da-wei ZHANG

Hong-xu LIU

Mei DAI

Yao HAN

Yong-cheng WANG

Zhao-yu LI

Xiao LI

Related Institution

Beijing Hospital of Traditional Chinese Medicine，Capital Medical University

Shandong University of Traditional Chinese Medicine（TCM），Ji'nan

Affiliated Hospital of Shandong University of TCM，Ji'nan

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰